Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
humanized anti-VEGF monoclonal antibody
- Development stage
- Unknown
- Lead developer
- Beijing Green Bamboo Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The humanized anti-VEGF monoclonal antibody (specifically the candidate LZ01) is a bevacizumab biosimilar developed by Beijing Green Bamboo Biotechnology. It is a recombinant humanized IgG1 monoclonal antibody designed to bind to and neutralize vascular endothelial growth factor (VEGF), a critical protein that stimulates angiogenesis (the formation of new blood vessels). By blocking the interaction of VEGF with its receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells, the antibody inhibits the proliferation of tumor vasculature, thereby starving the tumor of the blood supply necessary for growth and metastasis. This therapeutic candidate is primarily being evaluated for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC), with clinical studies focusing on demonstrating pharmacokinetic similarity and safety compared to the reference product, Avastin.
- Other names
- 人源化抗VEGF单抗注射液
02
Targets
Beyond the preview
Go deeper on humanized anti-VEGF monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on humanized anti-VEGF monoclonal antibody.